







SYSTEMATIC REVIEW

REVISED Effects of iron intake on neurobehavioural outcomes in African children: a systematic review and meta-analysis of randomised controlled trials [version 2; peer review: 1 approved, 1 approved with reservations]

Agnes M. Mutua ¹, Kelvinson Mwangi ¹, Amina Abubakar ¹⁻⁴, Sarah H. Atkinson ^{1,5,6}

¹Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine Research-Coast, KEMRI Wellcome Trust Research Programme, Kilifi, 230-80108, Kenya

²Institute for Human Development, Aga Khan University, Nairobi, 30270-00100, Kenya

³Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK

⁴Department of Public Health, School of Human and Health Sciences, Pwani University, Kilifi, 195-80108, Kenya

⁵Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, UK

⁶Department of Paediatrics, University of Oxford, Oxford, OX3 9DU, UK

v2 First published: 13 Jul 2021, 6:181
<https://doi.org/10.12688/wellcomeopenres.16931.1>

Latest published: 24 Nov 2021, 6:181
<https://doi.org/10.12688/wellcomeopenres.16931.2>

Abstract




Background: Iron deficiency and developmental delay are common in African children. While experimental studies indicate an important role of iron in brain development, effects of iron on child development remain unclear. We aimed to evaluate the effects of iron supplementation or fortification on neurobehavioural outcomes in African children and further summarise these effects in children living in non-African countries for comparison.



Methods: We searched PubMed, EMBASE, PsycINFO, Scopus and Cochrane Library for studies published up to 22nd October 2021. We included randomised controlled trials (RCTs) evaluating effects of iron supplementation or fortification on neurobehavioural outcomes in children. Due to heterogeneity in study methods, we analysed all studies qualitatively and in secondary analyses only seven RCTs with 11 arms were meta-analysed.

Results: We identified 2231 studies and included 35 studies (n=9988) in the systematic review. Only five studies (n=1294) included African children while 30 (n=8694) included children living in non-African countries. Of the five African studies, two (n=647) reported beneficial effects of iron supplementation on neurobehavioural outcomes in anaemic children, while three (n=647) found no beneficial effects. Of 30 studies in children living in non-African countries, 10 (n=3105) reported beneficial effects of iron supplementation or fortification on

Open Peer Review

Reviewer Status  

	Invited Reviewers	
	1	2
version 2		
(revision)		
24 Nov 2021	report	
version 1		
13 Jul 2021		
	report	report

1. **Patricia Kitsao-Wekulo** , African Population and Health Research Center, Nairobi, Kenya
2. **Michael Mireku** , University of Lincoln, Lincoln, UK

Any reports and responses or comments on the article can be found at the end of the article.

neurobehavioural outcomes, seven (n=786) reported beneficial effects only in children who had iron deficiency, iron deficiency anaemia or anaemia while 13 (n=4803) reported no beneficial effects.

Conclusions: There are few studies in African children despite the high burden of iron deficiency and developmental delay in this population. Evidence on the effects of iron supplementation on neurobehavioural outcomes remains unclear and there is need for further well-powered studies evaluating these effects in African populations.

PROSPERO registration: CRD42018091278 (20/03/2018)

Keywords

Iron deficiency, iron deficiency anaemia, African children, cognitive, motor, language, behaviour, development.



This article is included in the [KEMRI | Wellcome Trust gateway](#).

Corresponding authors: Agnes M. Mutua (amutua@kemri-wellcome.org), Sarah H. Atkinson (satkinson@kemri-wellcome.org)

Author roles: **Mutua AM:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Mwangi K:** Data Curation, Methodology, Writing – Review & Editing; **Abubakar A:** Conceptualization, Methodology, Supervision, Validation, Visualization, Writing – Review & Editing; **Atkinson SH:** Conceptualization, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [110255, <https://doi.org/10.35802/110255>; to SHA], the DELTAS Africa Initiative [DEL-15-003] and with core awards to the KEMRI-Wellcome Trust Research Programme [203077, <https://doi.org/10.35802/203077>] and the Medical Research Council award to AA [MR/M025454/1]. AMM was supported by a Wellcome Trust Master's Fellowship [209640, <https://doi.org/10.35802/209640>]. KM was supported through the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107769/Z/10/Z, <https://doi.org/10.35802/107769>] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Mutua AM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Mutua AM, Mwangi K, Abubakar A and Atkinson SH. **Effects of iron intake on neurobehavioural outcomes in African children: a systematic review and meta-analysis of randomised controlled trials [version 2; peer review: 1 approved, 1 approved with reservations]** Wellcome Open Research 2021, 6:181 <https://doi.org/10.12688/wellcomeopenres.16931.2>

First published: 13 Jul 2021, 6:181 <https://doi.org/10.12688/wellcomeopenres.16931.1>

REVISED Amendments from Version 1

We have revised the manuscript to address the comments and suggestions made by the reviewers. In the Introduction section, we have shifted the second paragraph on the burden of iron deficiency to the beginning of the section as it provides better context for the review. We have now abbreviated 'randomised controlled trials' after the first use, revised 'Sub-Saharan Africa' to 'sub-Saharan Africa' for consistency and changed 'study' to 'review'. In Methods, we have clarified that we did not restrict our search by publication date for comprehensiveness and have updated our search to 22nd October 2021 and added one more study. We have explained that the few disagreements between reviewers were on study methodologies in some of the identified studies and were resolved through discussion following our pre-determined inclusion and exclusion criteria. We have clarified that we summarized all the studies narratively and did a secondary meta-analysis for seven studies in non-African countries that used the same tool, the Bayley Scales of Infant Development. Also, we have edited the phrase 'meta-analysis was' to 'meta-analyses were'. In the Results and Discussion sections, we have generally removed repeated text and summarized the sections to improve readability. We have added a paragraph comparing studies in African countries versus non-African countries at the end of the Results section based on our second objective. We have moved the information on concerns around iron supplementation and increased risk of malaria from the Discussion to the Introduction section for better context. Lastly, we have clarified the methods for the meta-analysis of seven studies in non-African countries and highlighted that heterogeneity in the study methods was a main limitation that precluded a formal meta-analysis of all included studies. We have updated the abstract, all Figures, References and Extended data (supplementary materials) to reflect the changes made.

Any further responses from the reviewers can be found at the end of the article

Introduction

Iron deficiency is the most common micronutrient deficiency affecting about two billion individuals globally and accounting for over 40% of all cases of anaemia¹⁻³. Children living in Africa disproportionately bear the highest burden of anaemia and iron deficiency. Approximately 43% of pre-school children are anaemic globally and over 60% of these children live in Africa^{1,4}, while it is estimated that 52% of African children are iron deficient⁵.

Brain development begins at conception and continues into early adulthood⁶. During this period and particularly in the first five years of life, children living in Africa are vulnerable to impaired neurobehavioural development as a result of exposure to different risk factors including poverty, malnutrition and infectious diseases^{7,8}. About a third of pre-school children in low and middle-income countries (LMICs) are unlikely to reach their cognitive and/or socioemotional milestones and 44% of these children live in sub-Saharan Africa⁹. Long-term consequences of impaired child development include poor educational performance, low incomes and poor family planning, contributing to the cycle of poverty in LMICs⁸.

Iron deficiency and anaemia are important risk factors for impaired brain development in childhood^{10,11}. However,

epidemiological studies provide inconclusive evidence for the effects of iron supplementation or fortification on neurobehavioural outcomes despite compelling evidence from animal and *in vitro* studies. These studies indicate that iron plays an important role in neurotransmission, DNA synthesis and myelinogenesis¹²⁻¹⁴. Iron is also important for the synthesis of tryptophan hydroxylase and tyrosine hydroxylase, enzymes that are involved in the synthesis of serotonin, dopamine and norepinephrine, which are important for neurobehavioural processes in the brain^{14,15}. Iron deficiency is associated with long-term behavioural abnormalities and impaired dopaminergic-dependent synaptic plasticity in the hippocampus, which may result in learning and memory deficits^{16,17}.

Despite the high prevalence of both iron deficiency and anaemia, there are few studies investigating the effects of giving iron on neurobehavioural outcomes in African children. This may be due to many factors including concern that iron supplementation may increase the risk of malaria and other infections¹⁸⁻²⁰. In this systematic review and meta-analysis, our objective was to evaluate the effects of iron supplementation or fortification on neurobehavioural outcomes in children living in Africa. For comparison, we further summarised evidence from randomised controlled trials (RCTs) on the effects of iron supplementation on neurobehavioural outcomes in non-African countries.

Methods

Reporting guidelines

Our systematic review and meta-analyses were guided by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines²¹ and the protocol was registered on the PROSPERO database on 20th March 2018 (registration number CRD42018091278).

Search strategy and eligibility criteria

We searched PubMed, EMBASE, PsycINFO, Scopus and Cochrane Library for studies published up to 22nd October 2021. Additionally, we scanned reference lists of identified studies and previous systematic reviews. We conducted searches for RCTs using a search strategy combining Medical Subject Heading terms for [iron] AND [neurobehavioural outcomes] AND [children] AND [RCT 'publication type']. We modified the search strategy as appropriate for each of the specific databases (Extended data, file 1²¹). The search was not restricted by language or publication date.

We included studies that met the following criteria: (i) included participants aged below 18 years; (ii) RCTs of iron supplementation or fortification in children or pregnant mothers; (iii) assessed neurobehavioural outcomes in children including cognitive or motor development, intelligence quotient, attention, behaviour, educational achievement or language development. We excluded studies assessing neurobehavioural outcomes in adult participants and RCTs involving iron supplementation/fortification alongside other micronutrients or macronutrients that did not separately evaluate the effects of iron. We also excluded observational studies, reviews, case studies, abstracts, comments and study protocols.

Study selection, data extraction and quality appraisal

Two authors (AMM and KM) independently screened titles and abstracts of all identified studies against the inclusion criteria and then screened identified full texts to determine eligibility for inclusion. Disagreements between reviewers on study methodologies were resolved through discussion following the pre-determined inclusion and exclusion criteria. We extracted the following variables: study author(s) and year of publication, country, sample size, baseline iron status, age at iron supplementation and neurobehavioural assessment, neurobehavioural domain assessed and the tools used, definition of iron status and findings of the study.

We used the revised Cochrane risk-of-bias tool for randomised trials (RoB 2) to assess for risk of bias for the individually-randomised, parallel-group RCTs included in the review²². RoB 2 assesses five domains of bias including bias from the randomization process, deviations from intended interventions, missing outcome data, and bias in measurement of the outcome and selection of the reported result. To assess the risk of bias in two cluster RCTs, we used the revised Cochrane risk of bias tool for randomised trials with additional considerations for cluster-randomised trials²³.

Synthesis of included studies

The large degree of diversity in the study variables necessitated narrative synthesis of the study findings for all included studies. We grouped and discussed the studies based on the neurobehavioural domain assessed and summarised study characteristics and findings (Table 1 and Extended data, file 2²¹). Under each neurobehavioural domain, we first summarised studies in African countries followed by studies in non-African countries. We compared findings of studies from African and non-African countries and also studies that evaluated the effect of iron-fortified foods compared to non-fortified foods. We further compared study findings based on age (studies in infants versus older children) and baseline iron status (normal iron status versus iron deficiency, iron deficiency anaemia or anaemia).

Secondary meta-analysis of seven studies in non-African countries.

Due to the substantial variation in study methods, we did a secondary meta-analysis in a limited number of RCTs that all used the Bayley Scales of Infant Development (BSID) to assess cognitive and motor development in children living in non-African countries. None of the studies in African children used the BSID. In the meta-analysed studies, mean cognitive and motor development scores and standard deviations were reported. For each of the two domains, we generated forest plots to show the mean differences (MDs) and the weight of each study and the pooled effect size with their corresponding 95% confidence intervals (CIs). Heterogeneity between the studies was assessed using the I^2 statistic. We applied random-effects meta-analysis since the I^2 values were > 40%. All

analyses were conducted using STATA version 15.1 (StataCorp, College Station, TX 77845, USA).

Results

Study selection

We identified a total of 2231 papers from the database searches and an additional 18 papers from screening references of eligible papers (Figure 1). We removed 521 duplicates and after screening titles and abstracts, excluded 1647 papers that were not relevant to our review. We further excluded 14 RCTs because participants were randomised to multiple micronutrient powders or other nutritional supplements together with iron and the effect of iron supplementation was not evaluated separately from the other supplements. We excluded eight observational studies, six RCTs in adults and 15 papers that were literature reviews, study protocols, comments or abstracts. We excluded one study that did not have a placebo group as all participants received a single iron-dextran intramuscular injection. We further excluded one RCT in low birthweight children (<2500g) and another in premature children (born at 27 to 30 gestational weeks).

Study characteristics and outcomes

We included a total of 35 RCTs published between 1978 and 2021 (Figure 2). In total, five RCTs were in African countries while 30 RCTs were in non-African countries. Among the 35 RCTs were those that studied the effect of: iron supplementation compared to placebo or no treatment (n=25), iron-fortified foods compared to non-fortified foods (n=5), formula milk fortified with high compared to low dosages of iron (n=1), immediate iron supplementation given concurrently or 28 days after antimalarial treatment on development in children with severe malaria (n=1), varying and consistent doses of iron supplementation compared to placebo (n=1), and maternal iron supplementation on neurobehavioural outcomes in children after birth (n=2). Out of the 35 studies, two were in lead-exposed children at baseline. Overall, 11 studies were carried out in high-income countries and 24 in low and middle-income countries. The sample sizes ranged from 16 to 1358 and the RCTs provided varying forms of iron supplementation in varying dosages over periods ranging from 1 day to 15 months. The studies evaluated various neurobehavioural outcomes including cognitive, motor, language and behavioural development and educational achievement using a wide range of neuroassessment tools, the most common being the Bayley Scales of Infant Development. Iron status and anaemia were defined differently in the studies using varying iron biomarkers and haemoglobin (Hb) cut-offs. The characteristics of the included studies are shown in Table 1 and Extended data, file 2²¹. Of the 35 RCTs, 19 showed a low risk of bias, one showed a high risk of bias, while 15 studies were judged to raise some concerns (Extended data, files 3 and 4²¹). Some common limitations included a lack of description of the randomisation process and missing outcome data.

Table 1. Summary of studies assessing the effect of iron supplementation or fortification on neurobehavioural outcomes in African children: characteristics and findings.

Author, year (country)	Sample	Baseline iron status	Age at iron supplementation	Age at neuroassessment	Domain (assessment tool)	Intervention (duration)	Definition of iron status	Results
Ssemata, 2020 (Uganda) ²⁴	N=145 with cerebral malaria (75 received iron concurrently and 70 received iron 28 days after antimalarial treatment)	All children had ID	18 to 58.8 months	At 3 time-points: 18 months to 4.9 years, 24 to 64.8 months and 30 to 70.8 months	Cognitive Executive function Sustained attention Associative memory Socioemotional behaviour (MSEL, ECVT, COAT, CBCL, BRIEF-P, BRS)	Ferrous sulphate 2mg/kg/day either concurrently with antimalarial treatment or 28 days after receiving antimalarial treatment (3 months)	ID: ZnPP \geq 80 μ mol/mol heme	No difference in neurobehavioural scores between children who received iron supplementation concurrently or 28 days after antimalarial treatment.
Bouhouch, 2016 (Morocco) ²⁵	n=455 lead exposed children (110 received iron, 116 received iron+ EDTA, 112 received EDTA, and 117 received placebo)	Anaemia: 21% ID: 32%, 7% or 34% as defined by SF, TfR, or ZnPP	3 to 14 years	At 2 time-points: at baseline (3 to 14 years) and after supplementation.	Cognitive Memory (KABC-II, HVLIT)	2-3 biscuits (depending on body weight) containing 8 mg ferrous sulphate, 8 mg ferrous sulphate + 41 mg EDTA, 41 mg EDTA, or placebo (28 weeks)	ID: SF <12 mg/L for children <5 years, SF <15 mg/L for children \geq 5 years, or TfR >8.3 mg/L with (CRP \leq 5 mg/L, α 1-acid glycoprotein \leq 51 g/L) Anaemia: Hb <11.0 g/dL for children <5 years, Hb <11.5 g/dL for children 5-11 years, Hb <12.0 g/dL for children 12 years	No difference in cognitive or memory scores between children who received iron supplementation or placebo.

Author, year (country)	Sample	Baseline iron status	Age at iron supplementation	Age at neuroassessment	Domain (assessment tool)	Intervention (duration)	Definition of iron status	Results
Baumgartner, 2012 (South Africa) ²⁶	n=288 (70 received iron+ placebo, 72 placebo + DHA/EPA, 73 iron+ DHA/EPA, and 73 placebo + placebo)	Anaemia: 20.6-21.1% ID: 6.2% to 16%	6 to 11 years	At 2 time-points: at baseline (6 to 11 years) and after supplementation.	Cognitive Memory (HVLIT KABC)	50 mg iron sulphate +DHA/ EPA (420/80 mg), 50 mg iron sulphate+ placebo, DHA/ placebo+ DHA/ EPA, or placebo + placebo (8.5 months)	ID: SF<15 µg/L excluding children with CRP >5 mg/L or ZnPP >70 µmol/mol or TfR >8.3 mg/L Anaemia: Hb <11.5 g/dL IDA: anaemia + SF<15 µg/L	Anaemic children who received iron supplementation+ placebo had higher cognitive and memory scores compared to children who received placebo + placebo No difference in cognitive scores in children who received iron+ DHA/EPA compared to children who received placebo + placebo
Stoltzfus, 2001 (Zanzibar) ²⁷	n=359 (183 received iron and 176 placebo)	Anaemia: 97% Severe anaemia: 18%	6 to 59 months	At 2 timepoints: 6 to 59 months and 18 to 71 months	Language Motor (Parents reported motor and language milestones)	20 mg ferrous sulphate or placebo (12 months)	Anaemia: Hb<110g/l Severe anaemia: Hb<7 g/dL ID: SF<12 mg/L	Children who received iron supplementation had improved language scores compared to children who received placebo and children with baseline Hb<9 g/dL who received iron supplementation had improved motor scores compared to children who received placebo.
Boivin, 1993 (Zaire) ²⁸	N=47 (17 children received both anthelmintics and iron, 7 only iron, 8 only anthelmintics, and 15 did not receive either intervention)	Not indicated	23 boys (mean age=7.7, SD=0.8 years) and 24 girls (mean age=8.0, SD =1.8 years)	At baseline (mean age for boys=7.7, SD=0.8 years) and mean age for girls=8.0, SD =1.8 years) and 4 weeks after the 1st assessment	Cognitive (KABC)	20 mg iron (4 weeks)	Anaemia: Hb<12 g/dL	No difference in cognitive scores between children who received only iron supplementation or placebo.

BRIEF-P, Behavior Rating Inventory of Executive Functioning, Preschool edition; BRS, Behavior Rating Scales; CBLC, Child Behaviour checklist; CRP, C-reactive protein; COAT, Color Object Association Test; DHA/EPA, docosahexaenoic acid and eicosapentaenoic acid; ECVT, Early Childhood Vigilance Test; EDTA, ethylenediaminetetraacetic acid; Hb, haemoglobin; HVLIT, Hopkins Verbal Learning Test; ID, iron deficiency; KABC, Kaufman Assessment Battery for Children; SD, standard deviation; SF, serum ferritin; TfR, transferrin receptor; ZnPP, zinc protoporphyrin.




Figure 1. PRISMA flow chart showing the selection process for studies included in the review and meta-analysis.

Cognitive development

A total of 28 RCTs (n=7503) investigated the effect of iron supplementation (n=23) or fortification (n=5) on cognitive development. Out of these studies, four (n=935) were in African countries including two among children living in sub-Saharan Africa (n=433). One RCT of 288 South African children aged

six to 11 years reported improved cognitive and memory scores among anaemic children Hb<11.5 g/dL) who received iron supplementation for 8.5 months compared to children who received placebo²⁶. However, two RCTs, one in 455 lead-exposed Moroccan children aged three to 14 years and another in 47 Zairean school children aged seven to nine years, reported




Figure 2. Studies of the effect of iron supplementation or fortification on neurobehavioural outcomes in children. Five studies (n=1294) were in Africa, 15 (n=6169) in Asia, four (n=695) in Europe, nine (n=1332) in North America, one (n=196) in South America and one (n=302) in Australia.

that iron supplementation or fortification for four to 28 weeks was not beneficial for cognitive development^{25,28}. One RCT (n=145) without a placebo arm reported no improvement in cognitive development in Ugandan pre-school children with severe malaria who received iron supplementation concurrently or 28 days after antimalarial treatment²⁴.

In comparison, a total of 24 RCTs (n=6568) investigated the effect of iron supplementation or fortification on cognitive development in children living in non-African countries. Out of these 24 studies, three (n=604) reported beneficial effects on cognitive development, six (n=678) reported beneficial effects only in children with iron deficiency anaemia (IDA) at baseline, while 15 found no beneficial effects. Of the three studies reporting beneficial effects, one RCT of 73 adolescent girls in the USA reported improved verbal learning and memory after iron supplementation for eight weeks compared to placebo²⁹, another RCT of 391 Thai children reported improved intelligence quotient (IQ) scores in children who received once-a-week iron supplementation compared to those who received daily iron supplementation or placebo for 16 weeks³⁰, while one RCT of 140 Indian adolescents reported improved cognition in children who received iron-biofortified pearl millet compared to those who received conventional pearl millet³¹. Six studies reported improved cognitive development among children with IDA or anaemia at baseline. Of these six studies, four RCTs,

two in Indonesia (n=295), one in Costa Rica (n=191) and one in Greece (n=49), reported improved cognitive development after iron supplementation for two to four months in pre-school children^{32–35}. Another RCT in 24 pre-school American children with IDA reported improved cognitive development among those who received a single iron-dextran complex injection compared to a single sterile saline injection³⁶. One RCT (n=119) in Indonesia reported improved IQ among school children with IDA who received iron supplementation for three months compared to those who received placebo³⁷.

In total, 15 (n=5286) out of 24 studies found no beneficial effects of iron supplementation or fortification on cognitive development. Among pre-school children, seven RCTs, two in Turkey (n=124), one in Indonesia (n=655), one in Bangladesh (n=221), one in Chile (n=196), one in Costa Rica (n=86) and one in Guatemala (n=68) reported no beneficial effects of iron supplementation for one week to six months on cognitive development^{38–44}. Three RCTs in Canada (n=225), the UK (n=428) and Spain (n=133) reported no beneficial effects of iron-fortified formula on cognitive development in children aged six to nine months compared to unfortified formula milk, low-iron fortified formula or cow's milk^{45–47}. Among school children three RCTs, one in Thailand (n=1358), one in Sri-Lanka (n=1190) and one in Indonesia (n=130), reported that iron supplementation for three to six months was not beneficial for

cognition in children aged eight to 11.6 years^{33,48,49}. One RCT of 170 Indian adolescents found no beneficial effect of daily iron-fortified wheat-based meals for seven months on cognition compared to unfortified wheat-based meals⁵⁰. Another RCT in 302 Australian mother-child pairs reported no beneficial effects of iron supplementation during pregnancy on IQ at four years⁵¹. Secondary meta-analysis of seven studies (n=775) provided limited evidence of beneficial effects of iron supplementation on cognitive development in pre-school children (MD=1.73, 95% CI, -1.05, 4.52) (Extended data, file 5²¹).

Motor development

A total of 19 RCTs (n=4438) investigated the effect of iron supplementation (n=16) or fortification (n=3) on motor outcomes. Out of these studies, only one was in African children. One RCT of 359 children in Zanzibar reported improved motor and language scores in children with Hb<9 g/dL at baseline who received iron supplementation for 12 months compared to children who received placebo²⁷.

A total of 18 RCTs (n=4079) investigated the effect of iron supplementation or fortification on motor development in children living in non-African countries. Out of these 18 studies, seven (n=2479) reported beneficial effects on motor development, two (n=310) reported beneficial effects only in children with IDA at baseline, while nine (n=1290) found no beneficial effects. Of the seven studies reporting beneficial effects, one RCT of 1196 Chinese children aged six weeks whose mothers also received iron supplementation during pregnancy reported that iron supplementation for 7.5 months, with or without iron supplementation in pregnancy, improved gross motor development compared to placebo⁵². Four RCTs, one in Indonesia (n=655), one in India (n=180), one in the USA (n=97) and another in Canada (n=41) reported beneficial effects of iron supplementation for two to six months on motor development compared to placebo^{38,53-55}. Two RCTs, one in the UK (n=85) and another in Canada (n=225) reported improved motor development in children aged six to eight months who received iron-fortified formula milk for 10 to 15 months compared to children who received regular formula or cow's milk^{47,56}. Two studies reported improved motor development after iron supplementation among children with IDA at baseline. Two RCTs, one in Costa Rica (n=191) and one in Indonesia (n=119), reported that pre-school children with IDA who received iron supplementation for three to four months had improved motor development compared to children who received placebo^{33,35}.

Out of the 18 studies, nine found no beneficial effects of iron supplementation or fortification on motor development in pre-school children. Six RCTs, two in Turkey (n=124), one in Chile (n=196), one in Bangladesh (n=221), one in Costa Rica (n=96) and one in Guatemala (n=68) reported no beneficial effect of three to six months of iron supplementation compared to placebo³⁹⁻⁴⁴. Another small RCT in 24 pre-school American children with IDA reported no beneficial effects of a single iron-dextran complex injection on motor development³⁶. Two RCTs, in the UK (n=428) and Spain (n=133) reported no beneficial effects of iron-fortified formula

milk on motor development compared to unfortified formula, cow's milk or low-iron formula milk^{45,46}. The seven studies (n=775) included in a secondary meta-analysis showed no beneficial effects of iron supplementation on motor development in pre-school children (MD=1.99, 95% CI, -0.97, 4.95) (Extended data, file 6²¹).

Behavioural functioning

In total, eight RCTs (n=2295) investigated the effect of iron supplementation (n=7) or fortification (n=1) on behavioural functioning in children. Of these eight studies, only one (n=145) was in African children. One RCT of 145 Ugandan children aged 18 to 59 months with severe malaria reported no improvement in behavioural functioning in children who received iron supplementation concurrently or 28 days after antimalarial treatment²⁴. A total of seven RCTs (n=2150) investigated the effect of iron supplementation or fortification on behavioural functioning in children living in non-African countries. Of these seven studies, one (n=24) reported beneficial effects on behavioural functioning in children with IDA, while six (n=2126) reported no beneficial effects. One small RCT of 24 American pre-school children with IDA reported improved behavioural functioning among children who received a single iron-dextran complex injection³⁶. Of the six studies reporting no effect, three, one in Indonesia (n=655), one in Bangladesh (n=221) and one in Chile (n=196), reported no beneficial effects of iron supplementation for three to six months on behavioural functioning in children up to six months of age^{38,39,43}. One RCT of 527 lead-exposed Mexican children similarly reported no beneficial effect of iron supplementation for six months on behavioural functioning⁵⁷. Another RCT of 225 Canadian children aged six months found no beneficial effects of iron-fortified formula for 15 months on behaviour compared to regular formula⁴⁷, while one RCT in 302 Australian mother-child pairs reported no beneficial effects of iron supplementation during pregnancy on behaviour at four years⁵¹.

Educational achievement

Overall, five RCTs (n=3188) investigated the effect of iron supplementation on educational achievement in children living in non-African countries. There were no studies in African countries. One RCT of 130 Indonesian children aged 8 to 12 years reported improved educational achievement in anaemic children who received iron supplementation for three months compared to those who received placebo⁵⁸. Out of the five studies, four (n=3058) found no beneficial effects. Three RCTs, one in Sri Lanka (n=1190), one in Thailand (n=1358) and one in Indonesia (n=119) found no beneficial effects of iron supplementation for three to six months on educational achievement^{37,48,49}, while another RCT including 391 Thai school children reported no beneficial effect of once-a-week or daily iron supplementation for 16 weeks on educational achievement compared to placebo³⁰.

Effect of iron supplementation based on baseline iron status

Out of 18 studies (n=3524), 11 (n=2769) evaluated the effect of iron supplementation in groups of children with ID, IDA

or anaemia compared to children with normal iron status at baseline, five (n=698) included only children with ID, IDA or anaemia at baseline, while two (n=57) included only children with sufficient iron status at baseline. Of the 11 studies that compared groups, six (n=953) reported beneficial effects of iron supplementation on neurobehavioural outcomes in children with ID, IDA or anaemia compared to those with normal iron status^{26,32–35,58}, while five (n=1816) reported no beneficial effects^{40,42–44,49}. Of the five studies that included only children with ID, IDA or anaemia at baseline, four (n=553) reported beneficial effects of iron supplementation on neurobehavioural outcomes^{27,29,36,54}, while one (n=145) found no beneficial effects²⁴. Secondary sub-group meta-analysis based on baseline iron status in studies using the BSID indicated that iron supplementation was not beneficial for cognitive or motor development (Extended data, file 5 and 6²¹). However, these sub-group analyses were limited by the small sample sizes.

Effect of iron supplementation or fortification in children during infancy versus older age

Overall, ten RCTs (n=3180) evaluated the effect of iron supplementation (n=6) or fortification (n=4) on neurobehavioural outcomes during infancy and of these studies, six (n=2382) reported beneficial effects of iron supplementation (n=4) or fortification (n=2)^{38,43,52,53,55,56}, while four (n=798) found no beneficial effects of iron supplementation (n=2) or fortification (n=2)^{39,41,45,46}. In children above one year of age, 24 RCTs (n=6506) evaluated the effects of iron supplementation (n=22) or fortification (n=2) on neurobehavioural outcomes and of these, 13 (n=2156) reported a beneficial effect of iron supplementation (n=12) or fortification (n=1) on neurobehavioural outcomes^{26,27,29–37,54,58} while 11 (n=4350) reported no beneficial effects of iron supplementation (n=10) or fortification (n=1)^{24,25,28,40,42–44,48–50,57}.

Effect of duration of supplementation or fortification

In total, seven studies (n=534) investigated the effect of iron supplementation for less than three months and of these studies, five (n=419) reported beneficial effects of iron supplementation on neurobehavioural outcomes^{29,32,34,54}, while two (n=115) reported no beneficial effects^{28,44}. Out of 26 studies (n=8972) that evaluated the effect of iron supplementation (n=20) or fortification (n=6) for three months or more, 13 (n=3939) reported beneficial effects of iron supplementation (n=10) or fortification (n=3) on neurobehavioural outcomes^{26,27,30,31,33,35,37,38,47,52,53,56,58} and 13 (n=5033) reported no beneficial effects of iron supplementation (n=10) or fortification (n=3)^{24,25,39–43,45,46,48–50,57}.

Comparison of studies in African countries versus non-African countries

Five RCTs including a total of 1294 children evaluated the effect of iron supplementation or fortification on cognitive (n=4), motor (n=1), behavioural (n=1) or language (n=1) outcomes in African children. Only three out of the five studies were in sub-Saharan Africa and of the three one did not have a placebo group. Of the five studies, two (n=647) reported beneficial effects on cognitive, motor or language outcomes only in children with Hb<9 g/dL and <11.5 g/dL compared to children with higher

Hb levels^{26,27}, while three (n=647) reported no beneficial effects^{24,25,28}. Of the three studies that reported no beneficial effect of iron supplementation, one included only children with ID²⁴, one had a prevalence of 21% of anaemia²⁵ while one did not report baseline iron status²⁵. Among children living in non-African countries, 30 RCT (n=8694) investigated the effect of iron supplementation or fortification on neurobehavioural outcomes. Compared to studies in African children, over half of the 30 studies reported beneficial effects on neurobehavioural outcomes, mostly in children with ID, IDA or anaemia^{29–54,56–58}.

Discussion

In this systematic review and meta-analysis, we found mixed evidence for the effects of iron supplementation or fortification on neurobehavioural outcomes in children. Few studies have investigated the effects of iron supplementation on neurobehavioural outcomes in African children despite the high burden of both iron deficiency and developmental delay in this population. Evidence from other regions on the effects of iron on neurobehavioural outcomes may not be generalisable to African children as these effects may be mediated by different risk factors such as malnutrition and a high burden of infectious diseases including malaria, HIV, tuberculosis and helminthic infections⁵⁹. Of five studies in African children only three included children living in sub-Saharan Africa, which has the highest prevalence of malaria⁶⁰, and one of these three studies had no placebo arm²⁴. Additionally, only six observational studies have evaluated the associations between iron status and neurobehavioural outcomes in African children and their findings are inconsistent^{61–66}. While the World Health Organization recommends iron supplementation together with effective malaria treatment and prevention in children living in malaria-endemic areas, evidence on the optimal time for iron supplementation and its effects on neurobehavioural outcomes in African children is limited⁶⁷.

Little is known about the effects of iron supplementation or fortification on cognitive or language development and educational achievement in African children. Out of 5 studies we found mixed evidence for beneficial effects; two studies reported improved cognitive or language development in children with anaemia (Hb <9 g/dL and Hb <11.5 g/dL) compared to those with higher Hb levels^{22,27}, while three studies reported lack of beneficial effects, one of these studies included only iron deficient children and two did not evaluate the effects of iron based on baseline iron status^{24,25,28}. No studies in Africa have investigated the effects of giving iron on educational achievement. Evidence from observational studies in African children is also limited with only three studies investigating associations between baseline iron status or anaemia and cognitive or language development. These three observational studies in Ethiopia, Egypt and Benin reported no association between child or maternal iron status and cognitive or language development in young children^{62,64,66}. Lack of associations in these studies may be explained by the sufficient iron status of the participants. Similarly, evidence for the effects of iron intake on cognitive development or educational achievement in children living in non-African countries was limited with only nine of 24 RCTs

reporting beneficial effects, with six out of these nine in children with IDA. It is possible that some of the tools used to assess cognitive development detect broad aspects of cognition and may have limited sensitivity to smaller changes resulting from nutritional effects in specific elements of cognition such as attention and information processing speed⁶⁸. Effects of iron on aspects of cognition including concentration, memory, attention and IQ may mediate the reported improved educational achievement following iron supplementation in one study while the lack of beneficial effects observed in four of the 24 studies may be explained by the low prevalence of iron deficiency or anaemia at baseline^{48,49}. In contrast to epidemiological studies, evidence from animal studies consistently suggests that iron may impact cognitive and language development through its roles in myelination, dopamine metabolism and the structure and function of the hippocampus, the centre for memory and learning processes^{16,69,70}.

Only a single study has evaluated the effects of iron supplementation on motor development in African children. This study in young Tanzanian children reported improved motor development in anaemic (Hb <9 g/dL) African children²⁷. Improved motor development following iron supplementation may be attributed to improved iron status. Iron deficiency is associated with low cellular oxygen-carrying capacity of blood in tissues causing low muscle energy production which may limit independent effort and balance delaying acquisition of motor skills in children^{71,72}. Evidence from three observational studies in Zanzibar and Ghana reported that ID and/or IDA were associated with poor motor development in children^{61,63,65}. About half of the RCT studies in children living in non-African countries reported beneficial effects of iron supplementation on motor development. However, most of these studies did not explore the effects of iron supplementation based on iron status. The mixed findings may be explained by differences in study methods such as sample sizes and baseline iron status. Animal studies provide mechanistic evidence of how iron might influence motor development. Iron is important for myelination in the corticospinal and corticostriatal tracts, the main pathways for motor signals from the brain to the limbs⁷³. Additionally, iron plays an important role in dopamine function in the basal ganglia, an important area in the brain for motor function⁷⁴.

We found little evidence for the effects of iron supplementation on behavioural functioning. Only a single study has been conducted in African children and it reported no evidence of improved behavioural functioning in children who received iron supplementation concurrently or 28 days after antimalarial treatment. This study may be limited by the small sample size and lack of a placebo group. In children living in non-African countries, only one of five RCTs, in American children with IDA, reported beneficial effects. Children with IDA have been observed to be clumsy, inattentive, irritable and withdrawn, traits that are consistent with impaired behavioural functioning⁷⁵. The lack of beneficial effects of iron observed in some studies may be attributed to the small proportion of children with iron deficiency anaemia at baseline as mild iron deficiency may not result in depletion of iron in body tissues that would manifest in behavioural changes^{38,43}. Evidence from animal studies

indicate that iron may influence behavioural functioning through its role in dopaminergic neurotransmission which is key in behaviour activation and inhibition and reward seeking behaviour⁷⁶.

The mixed findings for the effects of iron supplementation on child development in our review may be attributed to differences in study methods, sensitivity of outcome measures used and populations. Based on baseline iron status, iron supplementation was mostly beneficial for development in children with iron deficiency or iron deficiency anaemia. Improvement of symptoms of iron deficiency or iron deficiency anemia, including lethargy and withdrawal, after iron supplementation may result in improved neurobehavioural outcomes in these children⁷⁷. Also, children with iron deficiency anaemia are likely to be fussy and clingy to their caregivers who may respond by holding them, which may delay the child's independent exploration and interaction with their environment and consequently delay neurobehavioural development⁷⁸. We observed little difference when comparing findings between studies that gave iron supplementation during or after infancy. Evidence indicates that iron supplementation may be more beneficial to child development in early childhood when there is rapid brain development but beneficial effects of iron supplementation on neurobehavioural outcomes have also been reported in older children^{79–81}. Only two studies evaluated the effects of maternal iron supplementation during pregnancy and they did not report beneficial effects on neurobehavioural outcomes in children after delivery^{51,52}. One of the studies reported that maternal iron supplementation did not improve iron status in the newborn as indicated by cord blood ferritin at delivery, which may explain the lack of beneficial effects on child development⁸². Further studies are necessary to evaluate the effects of maternal iron supplementation on neurobehavioural outcomes in children. We found little difference when comparing studies that gave iron supplementation for less than three months and studies that gave iron supplementation for three months or more. The World Health Organization recommends iron supplementation for three consecutive months in children living in areas with a high prevalence of anaemia for prevention of iron deficiency and anaemia, but it is unclear if this duration is adequate to improve neurobehavioural outcomes in children⁶⁷.

We identified five systematic reviews and meta-analyses of the effects of iron on neurobehavioural outcomes in children. Consistent with our review, one recent systematic review of 25 RCTs and 26 observational studies reported inconsistent findings for the effects of maternal or child iron supplementation or iron status on neurobehavioural outcomes in children⁸³. This systematic review only included studies with children below four years of age. Another systematic review and meta-analysis of 33 RCTs evaluating the effects of daily iron supplementation on child health reported no beneficial effects of iron supplementation on mental or psychomotor development in children aged four to 23 months⁸⁴. Of the 33 included studies, only six studies evaluated cognitive and psychomotor development in children. One systematic review and meta-analysis of 32 RCTs investigating the effects of daily supplementation on child health reported beneficial effects of iron supplementation

on cognition and IQ among anaemic children and aspects of attention and concentration in children aged five to 12 years⁸¹. Of the eligible 32 RCTs, only 12 assessed aspects of cognition in children and unlike our review, did not include studies that assessed other neurobehavioural domains. One Cochrane systematic review of eight RCTs assessing the effects of iron supplementation in children below three years of age who had iron deficiency reported no beneficial effects of iron supplementation on mental or psychomotor development⁸⁵. Another systematic review and meta-analysis of 14 RCTs evaluating the effects of oral iron supplementation in older school children and women reported beneficial effects of iron supplementation on attention, concentration and IQ but not memory, psychomotor function or school achievement⁷⁹.

Strengths and limitations

Strengths of our review include a very comprehensive search strategy of five databases without restrictions in geographical location, language or date of publication. To our knowledge, our review is the first to summarise evidence on the effects of iron supplementation on neurobehavioural outcomes in African children in comparison to evidence in children living in non-African countries. Our review highlights that very few studies have been conducted in Africa, with only three conducted in sub-Saharan Africa. Additionally, our review included children up to the age of 18 years giving an overview of neurobehavioural outcomes across childhood. Limitations of our review were the inability to conduct a quantitative meta-analysis due to substantial heterogeneity in study populations and methods including the tools used to assess neurobehavioural outcomes and definitions for iron status. Our secondary meta-analyses are likely to be limited by small sample sizes and other unstandardized factors including age, dosage and duration of iron supplementation.

Conclusions

We found conflicting evidence for the effects of iron supplementation or fortification on neurobehavioural outcomes in children and there were few studies in African children. Further, well-powered RCTs on the effects of iron supplementation on neurobehavioural outcomes in African children are needed considering the high burden of both iron deficiency and developmental delay in these populations. These studies further need to consider the impact of other risk factors such as infections and malnutrition on the relationship between iron and neurobehavioural outcomes in African children. Additionally, well-validated and standardised tools for assessing

neurobehavioural outcomes across all age groups in childhood would help in comparison of findings in studies.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

Figshare: Effects of iron intake on neurobehavioural outcomes in African children: a systematic review and meta-analysis of randomised controlled trials-supplementary files. <https://doi.org/10.6084/m9.figshare.14473077.v5>²¹.

This project contains the following extended data:

- Extended datafile 1: Search terms.
- Extended datafile 2: Summary of studies assessing the effect of iron supplementation or fortification on neurobehavioural outcomes in children living in non-African countries: characteristics and findings.
- Extended datafile 3: Assessment of risk of bias in randomised parallel-group trials included in the review using the revised Cochrane risk-of-bias tool for randomised trials.
- Extended datafile 4: Assessment of risk of bias in cluster-randomised parallel-group trials included in the review using the revised Cochrane risk-of-bias tool for randomised trials with additional considerations for cluster-randomised trials.
- Extended datafile 5: Forest plot for the effects of iron supplementation on cognitive development: overall effect and subgroup analyses based on baseline iron status.
- Extended datafile 6: Forest plot for the effects of iron supplementation on motor development: overall effect and subgroup analyses based on baseline iron status.

Reporting guidelines

Figshare: PRISMA checklist for Effects of iron intake on neurobehavioural outcomes in African children: a systematic review and meta-analysis of randomised controlled trials. <https://doi.org/10.6084/m9.figshare.14473077.v5>²¹.

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

References

1. Kassebaum NJ, Jasrasaria R, Naghavi M, *et al.*: **A systematic analysis of global anemia burden from 1990 to 2010.** *Blood*. 2014; **123**(5): 615–624.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Petry N, Olofin I, Hurrell RF, *et al.*: **The Proportion of Anemia Associated with**

Iron Deficiency in Low, Medium, and High Human Development Index Countries: A Systematic Analysis of National Surveys. *Nutrients*. 2016; **8**(11): 693.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

3. Vos T, Abajobir AA, Abate KH, *et al.*: **Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.** *Lancet*. 2017; **390**(10100): 1211–1259.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. World Health Organization: **Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations.** World Health Organization; 2011.
[Reference Source](#)
5. Muriuki JM, Mentzer AJ, Webb EL, *et al.*: **Estimating the burden of iron deficiency among African children.** *BMC Med*. 2020; **18**(1): 31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Tierney AL, Nelson CA: **Brain development and the role of experience in the early years.** *Zero Three* 3rd. 2009; **30**(2): 9–13.
[PubMed Abstract](#) | [Free Full Text](#)
7. Cordeiro CN, Tsimis M, Burt I: **Infections and brain development.** *Obstet Gynecol Surv*. 2015; **70**(10): 644–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Grantham-McGregor S, Cheung YB, Cueto S, *et al.*: **Developmental potential in the first 5 years for children in developing countries.** *Lancet*. 2007; **369**(9555): 60–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. McCoy DC, Peet ED, Ezzati M, *et al.*: **Early Childhood Developmental Status in Low- and Middle-Income Countries: National, Regional, and Global Prevalence Estimates Using Predictive Modeling.** *PLoS Med*. 2016; **13**(6): e1002034.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Black MM: **Micronutrient deficiencies and cognitive functioning.** *J Nutr*. 2003; **133**(11 Suppl 2): 3927S–3931S.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Bourre JM: **Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients.** *J Nutr Health Aging*. 2006; **10**(5): 377–85.
[PubMed Abstract](#)
12. Puig S, Ramos-Alonso L, Romero AM, *et al.*: **The elemental role of iron in DNA synthesis and repair.** *Metallomics*. 2017; **9**(11): 1483–1500.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Todorich B, Pasquini JM, Garcia CI, *et al.*: **Oligodendrocytes and myelination: the role of iron.** *Glia*. 2009; **57**(5): 467–478.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Youdim MB, Green AR: **Iron deficiency and neurotransmitter synthesis and function.** *Proc Nutr Soc*. 1978; **37**(2): 173–179.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Lozoff B, Georgieff MK: **Iron deficiency and brain development.** *Semin Pediatr Neurol*. Elsevier, 2006; **13**(3): 158–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Beard JL, Felt B, Schallert T, *et al.*: **Moderate iron deficiency in infancy: biology and behavior in young rats.** *Behav Brain Res*. 2006; **170**(2): 224–232.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Breton AB, Fox JA, Brownson MP, *et al.*: **Postnatal nutritional iron deficiency impairs dopaminergic-mediated synaptic plasticity in the CA1 area of the hippocampus.** *Nutr Neurosci*. 2015; **18**(6): 241–247.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Clark MA, Goheen MM, Fulford A, *et al.*: **Host iron status and iron supplementation mediate susceptibility to erythrocytic stage *Plasmodium falciparum*.** *Nat Commun*. 2014; **5**: 4446.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Muriuki JM, Mentzer AJ, Kimita W, *et al.*: **Iron status and associated malaria risk among African children.** *Clin Infect Dis*. 2019; **68**(11): 1807–1814.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Sazawal S, Black RE, Ramsan M, *et al.*: **Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial.** *Lancet*. 2006; **367**(9505): 133–143.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Mutua AM, Mwangi K, Abubakar A, *et al.*: **Effects of iron intake on neurobehavioural outcomes in African children: a systematic review and meta-analysis of randomized controlled trials-supplementary files.** *figshare*. Figure, 2021.
<http://www.doi.org/10.6084/m9.figshare.14473077.v3>
22. Sterne JAC, Savović J, Page MJ, *et al.*: **RoB 2: a revised tool for assessing risk of bias in randomised trials.** *BMJ*. 2019; **366**: i4898.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Eldridge S, Campbell M, Campbell M, *et al.*: **Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials.** 2016.
[Reference Source](#)
24. Ssemata AS, Hickson M, Ssenkusu JM, *et al.*: **Delayed iron does not alter cognition or behavior among children with severe malaria and iron deficiency.** *Pediatr Res*. 2020; **88**(3): 429–437.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Bouhouch RR, El-Fadeli S, Andersson M, *et al.*: **Effects of wheat-flour biscuits fortified with iron and EDTA, alone and in combination, on blood lead concentration, iron status, and cognition in children: A double-blind randomized controlled trial.** *Am J Clin Nutr*. 2016; **104**(5): 1318–1326.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Baumgartner J, Smuts CM, Malan L, *et al.*: **Effects of iron and n-3 fatty acid supplementation, alone and in combination, on cognition in school children: A randomized, double-blind, placebo-controlled intervention in South Africa.** *Am J Clin Nutr*. 2012; **96**(6): 1327–1338.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Stoltzfus RJ, Kvalsvig JD, Chwaya HM, *et al.*: **Effects of iron supplementation and anthelmintic treatment on motor and language development of preschool children in Zanzibar: Double blind, placebo controlled study.** *BMJ*. 2001; **323**(7326): 1389–1393.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Boivin MJ, Giordani B: **Improvements in cognitive performance for schoolchildren in Zaire, Africa, following an iron supplement and treatment for intestinal parasites.** *J Pediatr Psychol*. 1993; **18**(2): 249–264.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Bruner AB, Joffe A, Duggan AK, *et al.*: **Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls.** *Lancet*. 1996; **348**(9033): 992–996.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Sungthong R, Mo-Suwan L, Chongsuvivatwong V, *et al.*: **Once-weekly and 5-days a week iron supplementation differentially affect cognitive function but not school performance in Thai children.** *J Nutr*. 2004; **134**(9): 2349–2354.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Scott SP, Murray-Kolb LE, Wenger MJ, *et al.*: **Cognitive Performance in Indian School-Going Adolescents Is Positively Affected by Consumption of Iron-Biofortified Pearl Millet: A 6-Month Randomized Controlled Efficacy Trial.** *J Nutr*. 2018; **148**(9): 1462–1471.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Metallinos-Katsaras E, Valassi-Adam E, Dewey KG, *et al.*: **Effect of iron supplementation on cognition in Greek preschoolers.** *Eur J Clin Nutr*. 2004; **58**(11): 1532–1542.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Idjradinata P, Pollitt E: **Reversal of developmental delays in iron-deficient anaemic infants treated with iron.** *Lancet*. 1993; **341**(8836): 1–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Soewondo S, Husaini M, Pollitt E: **Effects of iron deficiency on attention and learning processes in preschool children: Bandung, Indonesia.** *Am J Clin Nutr*. 1989; **50**(3 Suppl): 667–673; discussion 673–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Lozoff B, Brittenham GM, Wolf AW, *et al.*: **Iron deficiency anemia and iron therapy effects on infant developmental test performance.** *Pediatrics*. 1987; **79**(6): 981–995.
[PubMed Abstract](#)
36. Oski FA, Honig AS: **The effects of therapy on the developmental scores of iron-deficient infants.** *J Pediatr*. 1978; **92**(1): 21–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Soemantri AG, Pollitt E, Kim I: **Iron deficiency anemia and educational achievement.** *Am J Clin Nutr*. 1985; **42**(6): 1221–1228.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Lind T, Lonnérdal B, Stenlund H, *et al.*: **A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: Effects on growth and development.** *Am J Clin Nutr*. 2004; **80**(3): 729–736.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Black MM, Baqui AH, Zaman K, *et al.*: **Iron and zinc supplementation promote motor development and exploratory behavior among Bangladeshi infants.** *Am J Clin Nutr*. 2004; **80**(4): 903–910.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Akman M, Cebeci D, Okur V, *et al.*: **The effects of iron deficiency on infants' developmental test performance.** *Acta Paediatr*. 2004; **93**(10): 1391–1396.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Yalçın SS, Yurdakök K, Açıkgöz D, *et al.*: **Short-term developmental outcome of iron prophylaxis in infants.** *Pediatr Int*. 2000; **42**(6): 625–630.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Lozoff B, Wolf AW, Jimenez E: **Iron-deficiency anemia and infant development: effects of extended oral iron therapy.** *J Pediatr*. 1996; **129**(3): 382–389.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Walter T, De Andrada I, Chadud P, *et al.*: **Iron deficiency anemia: adverse effects on infant psychomotor development.** *Pediatrics*. 1989; **84**(1): 7–17.
[PubMed Abstract](#)
44. Lozoff B, Brittenham GM, Viteri FE, *et al.*: **The effects of short-term oral iron therapy on developmental deficits in iron-deficient anemic infants.** *J Pediatr*. 1982; **100**(3): 351–357.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Iglesias Vázquez L, Canals J, Voltas N, *et al.*: **Does the fortified milk with high iron dose improve the neurodevelopment of healthy infants? Randomized controlled trial.** *BMC Pediatr*. 2019; **19**(1): 315.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

46. Morley R, Abbott R, Fairweather-Tait S, *et al.*: **Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial.** *Arch Dis Child.* 1999; **81**(3): 247–252.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Moffatt ME, Longstaffe S, Besant J, *et al.*: **Prevention of iron deficiency and psychomotor decline in high-risk infants through use of iron-fortified infant formula: A randomized clinical trial.** *J Pediatr.* 1994; **125**(4): 527–534.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Ebenezer R, Gunawardena K, Kumarendran B, *et al.*: **Cluster-randomised trial of the impact of school-based deworming and iron supplementation on the cognitive abilities of schoolchildren in Sri Lanka's plantation sector.** *Trop Med Int Health.* 2013; **18**(8): 942–951.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Pollitt E, Hathirai P, Kotchabhakdi NJ, *et al.*: **Iron deficiency and educational achievement in Thailand.** *Am J Clin Nutr.* 1989; **50**(3 Suppl): 687–696; discussion 696–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Muthayya S, Thankachan P, Hirve S, *et al.*: **Iron fortification of whole wheat flour reduces iron deficiency and iron deficiency anemia and increases body iron stores in Indian school-aged children.** *J Nutr.* 2012; **142**(11): 1997–2003.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Zhou SJ, Gibson RA, Crowther CA, *et al.*: **Effect of iron supplementation during pregnancy on the intelligence quotient and behavior of children at 4 y of age: long-term follow-up of a randomized controlled trial.** *Am J Clin Nutr.* 2006; **83**(5): 1112–1117.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Angulo-Barroso RM, Li M, Santos DC, *et al.*: **Iron Supplementation in Pregnancy or Infancy and Motor Development: a Randomized Controlled Trial.** *Pediatrics.* 2016; **137**(4): e20153547.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Friel JK, Aziz K, Andrews WL, *et al.*: **A double-masked, randomized control trial of iron supplementation in early infancy in healthy term breast-fed infants.** *J Pediatr.* 2003; **143**(5): 582–586.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Aukett MA, Parks YA, Scott PH, *et al.*: **Treatment with iron increases weight gain and psychomotor development.** *Arch Dis Child.* 1986; **61**(9): 849–857.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Bora R, Ramasamy S, Brown B, *et al.*: **Effect of iron supplementation from neonatal period on the iron status of 6-month-old infants at-risk for early iron deficiency: a randomized interventional trial.** *J Matern Fetal Neonatal Med.* 2021; **34**(9): 1421–1429.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Williams J, Wolff A, Daly A, *et al.*: **Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: Randomised study.** *BMJ.* 1999; **318**(7185): 693–697.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Kordas K, Stoltzfus RJ, López P, *et al.*: **Iron and zinc supplementation does not improve parent or teacher ratings of behavior in first grade Mexican children exposed to lead.** *J Pediatr.* 2005; **147**(5): 632–639.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Soemantri AG: **Preliminary findings on iron supplementation and learning achievement of rural Indonesian children.** *Am J Clin Nutr.* 1989; **50**(3 Suppl): 698–701; discussion 701–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Foote EM, Sullivan KM, Ruth LJ, *et al.*: **Determinants of anemia among preschool children in rural, western Kenya.** *Am J Trop Med Hyg.* 2013; **88**(4): 757–764.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. World Health Organization. **World Malaria Report 2019.** World Health Organization: Geneva, 2019; 185.
[Reference Source](#)
61. Angulo-Barroso RM, Schapiro L, Liang W, *et al.*: **Motor development in 9-month-old infants in relation to cultural differences and iron status.** *Dev Psychobiol.* 2011; **53**(2): 196–210.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Gashu D, Stoecker BJ, Bougma K, *et al.*: **Stunting, selenium deficiency and anemia are associated with poor cognitive performance in preschool children from rural Ethiopia.** *Nutr J.* 2016; **15**: 38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Kariger PK, Stoltzfus RJ, Olney D, *et al.*: **Iron deficiency and physical growth predict attainment of walking but not crawling in poorly nourished Zanzibari infants.** *J Nutr.* 2005; **135**(4): 814–819.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Mireku MO, Davidson LL, Boivin MJ, *et al.*: **Prenatal iron deficiency, neonatal ferritin, and infant cognitive function.** *Pediatrics.* 2016; **138**(6): e20161319.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Olney DK, Pollitt E, Kariger PK, *et al.*: **Young Zanzibari children with iron deficiency, iron deficiency anemia, stunting, or malaria have lower motor activity scores and spend less time in locomotion.** *J Nutr.* 2007; **137**(12): 2756–2762.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Youssef MAM, Hassan ES, Yasién DG: **Effect of Iron Deficiency Anemia on Language development in Preschool Egyptian children.** *Int J Pediatr Otorhinolaryngol.* 2020; **135**: 110114.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. World Health Organization. **Guideline: Daily iron supplementation in infants and children.** Geneva: World Health Organization. 2016.
[Reference Source](#)
68. Hughes D, Bryan J: **The assessment of cognitive performance in children: considerations for detecting nutritional influences.** *Nutr Rev.* 2003; **61**(12): 413–422.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Carlson ES, Tkac I, Magid R, *et al.*: **Iron is essential for neuron development and memory function in mouse hippocampus.** *J Nutr.* 2009; **139**(4): 672–679.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Bastian TW, von Hohenberg WC, Mickelson DJ, *et al.*: **Iron deficiency impairs developing hippocampal neuron gene expression, energy metabolism, and dendrite complexity.** *Dev Neurosci.* 2016; **38**(4): 264–276.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Haas JD, Brownlie IVT: **Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship.** *J Nutr.* 2001; **131**(2S–2): 676S–688S; discussion 688S–690S.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Pollitt E: **A developmental view of the undernourished child: background and purpose of the study in Pangalengan, Indonesia.** *Eur J Clin Nutr.* 2000; **54** Suppl 2: S2–S10.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Rothwell J, Lennon S: **Control of human voluntary movement.** *Physiotherapy.* 1994; **80**: 869.
[Publisher Full Text](#)
74. Beard JL, Connor JR: **Iron status and neural functioning.** *Annu Rev Nutr.* 2003; **23**: 41–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Lozoff B, Corapci F, Burden MJ, *et al.*: **Preschool-aged children with iron deficiency anemia show altered affect and behavior.** *J Nutr.* 2007; **137**(3): 683–689.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Schallert T, Petrie BF, Whishaw IQ: **Neonatal dopamine depletion: spared and unsparing sensorimotor and attentional disorders and effects of further depletion in adulthood.** *Psychobiology.* 1989; **17**: 386–396.
[Reference Source](#)
77. Sen A, Kanani SJ: **Deleterious functional impact of anemia on young adolescent school girls.** *Indian Pediatr.* 2006; **43**(3): 219–26.
[PubMed Abstract](#)
78. Lozoff B, Klein NK, Nelson EC, *et al.*: **Behavior of infants with iron-deficiency anemia.** *Child Dev.* 1998; **69**(1): 24–36.
[PubMed Abstract](#)
79. Falkingham M, Abdelhamid A, Curtis P, *et al.*: **The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis.** *Nutr J.* 2010; **9**: 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Iannotti LL, Tielsch JM, Black MM, *et al.*: **Iron supplementation in early childhood: health benefits and risks.** *Am J Clin Nutr.* 2006; **84**(6): 1261–1276.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Low M, Farrell A, Biggs BA, *et al.*: **Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials.** *CMAJ.* 2013; **185**(17): E791–E802.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Zhao G, Xu G, Zhou M, *et al.*: **Prenatal iron supplementation reduces maternal anemia, iron deficiency, and iron deficiency anemia in a randomized clinical trial in rural China, but iron deficiency remains widespread in mothers and neonates.** *J Nutr.* 2015; **145**(8): 1916–1923.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. McCann S, Perapoch Amadó M, Moore SE: **The role of iron in brain development: A systematic review.** *Nutrients.* 2020; **12**(7): 2001.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Pasricha SR, Hayes E, Kalumba K, *et al.*: **Effect of daily iron supplementation on health in children aged 4–23 months: a systematic review and meta-analysis of randomised controlled trials.** *Lancet Glob Health.* 2013; **1**(2): e77–e86.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Wang B, Zhan S, Gong T, *et al.*: **Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anaemia.** *Cochrane Database Syst Rev.* 2013; **2013**(6): CD001444.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 2

Reviewer Report 25 November 2021

<https://doi.org/10.21956/wellcomeopenres.19259.r47218>

© 2021 Kitsao-Wekulo P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Patricia Kitsao-Wekulo 

Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya

I am satisfied with the changes made and have no further comments to make.

Competing Interests: I am a member of the Project Advisory Board for a project on which one of the authors, Amina Abubakar, is a principal investigator

Reviewer Expertise: Developmental psychology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 05 October 2021

<https://doi.org/10.21956/wellcomeopenres.18683.r45469>

© 2021 Mireku M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Michael Mireku 

School of Psychology, University of Lincoln, Lincoln, UK

Matua *et al.* have done excellent work on a very difficult topic. The authors attempted to investigate the effect of iron supplementation and fortification on neurobehavioural outcomes in children. The objective although clearly stated is very difficult to accurately investigate because of

several reasons:

1. There are several domains of neurobehavioural outcomes assessed in most papers;
2. Different assessment scales are used across several studies and the scores generated from one scale are not easily interchangeable/transferable into another scale;
3. Some of these scales are adapted for use in specific countries and others are not;
4. Age-dependent dose of iron supplementation will vary for different settings. Trials that recruit only iron-deficient children may provide a relatively higher dose of iron relative to studies in a general, supposedly healthy population. Thus, the benefit of iron supplementation may be the same across groups because of the dose. the same can be said for fortification - how much of the fortified product is the child consuming?

The authors have therefore done a very good job in identifying these potential issues and providing their analysis under these specific subheadings.

My only major concern is the validity of the meta-analysis in relation to the standardisation of the scales used to assess cognitive and motor functions. The authors failed to explain how they used the scores from the different scales in the meta-analysis.

Further, findings from the meta-analysis are actually scanty for the obvious reason of heterogeneity across studies. This should be discussed further.

Minor comment: Revise the first sentence under Methods "...metanalysis were" not "...metanalysis was"

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Partly

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Perinatal and paediatric epidemiology; Sleep health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Nov 2021

Agnes Mutua, Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine Research-Coast, KEMRI Wellcome Trust Research Programme, Kilifi, Kenya

We are grateful to the reviewer for his insightful comments and have addressed the below:

Mutua *et al.* have done excellent work on a very difficult topic. The authors attempted to investigate the effect of iron supplementation and fortification on neurobehavioural outcomes in children. The objective although clearly stated is very difficult to accurately investigate because of several reasons:

1. There are several domains of neurobehavioural outcomes assessed in most papers;
2. Different assessment scales are used across several studies and the scores generated from one scale are not easily interchangeable/transferable into another scale;
3. Some of these scales are adapted for use in specific countries and others are not;
4. Age-dependent dose of iron supplementation will vary for different settings. Trials that recruit only iron-deficient children may provide a relatively higher dose of iron relative to studies in a general, supposedly healthy population. Thus, the benefit of iron supplementation may be the same across groups because of the dose. the same can be said for fortification - how much of the fortified product is the child consuming?

The authors have therefore done a very good job in identifying these potential issues and providing their analysis under these specific subheadings.

My only major concern is the validity of the meta-analysis in relation to the standardisation of the scales used to assess cognitive and motor functions. The authors failed to explain how they used the scores from the different scales in the meta-analysis. Further, findings from the meta-analysis are actually scanty for the obvious reason of heterogeneity across studies. This should be discussed further.

Response: We thank the reviewer for this comment and agree that a main limitation of the review is the high level of heterogeneity in the studies which precluded a meta-analysis. We therefore analysed all studies in African and non-African countries qualitatively by summarizing the findings.

In secondary analyses we performed a meta-analysis of all studies (n=7) which used the same tool, the Bayley Scales of Infant Development, to assess cognitive and motor development. The Bayley Scales of Infant Development has standardized scales and therefore there was no need for any further standardization of the scores. We agree that these secondary analyses had a number of limitations. First, only a very limited number of studies used the Bayley Scales, which may introduce bias. Second, we were not able to meta-analyse African studies since this tool was not used and Bayley Scales are likely to be less applicable in this population. Third, although the meta-analysis included standardized assessment of neurodevelopmental outcomes many other factors were not standardized including dose and duration of iron supplementation.

We have now added a sub-heading to highlight the sub-section detailing the meta-analysis in the methods section as follows:

"Secondary meta-analysis of seven studies in non-African countries"

Due to the substantial variation in study methods, we did a secondary meta-analysis in a limited number of RCTs that all used the Bayley Scales of Infant Development (BSID) to assess cognitive and motor development in children living in non-African countries. None of the studies in African children used the BSID. In the meta-analysed studies, mean cognitive and motor development scores and standard deviations were reported. For each of the two domains, we generated forest plots to show the mean differences (MDs) and the weight of each study and the pooled effect size with their corresponding 95% confidence intervals (CIs). Heterogeneity between the studies was assessed using the I² statistic. We applied random-effects meta-analysis since the I² values were > 40%. All analyses were conducted using STATA version 15.1 (StataCorp, College Station, TX 77845, USA)."

We have summarized the results of the meta-analysis in the results section as follows:

'Cognitive development': "Secondary meta-analysis of seven studies (n=775), provided limited evidence of beneficial effects of iron supplementation on cognitive development in pre-school children (MD=1.73, 95% CI, -1.05, 4.52)."

'Motor development': "The seven studies(n=775) included in a secondary meta-analysis showed no beneficial effects of iron supplementation on motor development in pre-school children (MD=1.99, 95% CI, -0.97, 4.95) (Extended data, file 6)."

We have also noted this limitation in the Discussion section under 'Strengths and limitations':

"Limitations of our review were the inability to conduct a quantitative meta-analysis due to the substantial heterogeneity in study populations and methods including the tools used to assess neurobehavioural outcomes and definitions for iron status. Our secondary meta-analyses are likely to be limited by the small sample sizes and other unstandardized factors including age, dosage and duration of iron supplementation."

Minor comment: Revise the first sentence under Methods "...metanalysis were" not "...metanalysis was"

Response: We have now edited the sentence under 'Methods' as follows:

"Our systematic review and meta-analyses were guided by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines and the protocol was registered on the PROSPERO database on 20th March 2018 (registration number CRD42018091278)."

Competing Interests: No competing interests were disclosed.

Reviewer Report 06 August 2021

<https://doi.org/10.21956/wellcomeopenres.18683.r44987>

© 2021 Kitsao-Wekulo P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Patricia Kitsao-Wekulo**

Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya

The authors have presented data from a systematic review and meta-analysis which found mixed evidence for the effects of iron supplementation or fortification on neurobehavioural outcomes in children. This is an area on which there is limited evidence from Africa, despite the high prevalence of both iron deficiency and developmental delay. The authors are commended for the use of a comprehensive search strategy for their review which yielded important evidence on the effects of iron supplementation on neurobehavioural outcomes in African children, while at the same time comparing their findings with those from children living in non-African countries.

I have made the following comments for consideration by the authors:

Introduction

- The rationale for, and the objectives of the systematic review are clearly stated. However, I would like to suggest that the authors consider shifting some of the material in the Introduction. For instance, the second paragraph could be shifted to the beginning of this section as it gets straight to the point in providing context for the review.
- The first mention of 'randomised controlled trials' appears at the end of the introduction, and it is here that the abbreviation 'RCT' should appear after it has been written out in full. In later sections, the authors can just use the abbreviation, without having to spell it out in full again as they have done under the Methods and other sections.

Methods

- Under the subsection on the **search strategy**, the authors indicate that they 'searched...for studies published up to 9th March 2021.' It is not clear which month/ year was considered as the start point.
- 'Disagreements between reviewers were resolved through discussion.' Please clarify what the disagreements were on and the content of the discussion to get to a consensus.
- 'We used the revised Cochrane risk-of-bias tool for randomised trials...' This statement appears twice in the same paragraph. Consider revising.
- 'The large degree of diversity in the study variables necessitated narrative synthesis of the study findings.' Was this applied to all the studies included in the review, or only to those from Africa? Please clarify

Results

- '...that were not relevant to our study.' I suggest you use 'review' rather than 'study'
- The information on the time period of the publications included in the review should be provided earlier, under search strategy
- 'Of the 34 RCT studies: 25 evaluated the effect of iron supplementation compared to placebo or no treatment; five the effect of iron-fortified foods compared to non-fortified foods; one the effect of fortification of formula milk with high compared to low dosages of

iron; one the effect of immediate iron supplementation given concurrently or 28 days after antimalarial treatment on development in children with severe malaria and one the effect of varying and consistent doses of iron supplementation compared to placebo; two the effects of maternal iron supplementation on neurobehavioural outcomes in children after birth.' For clarity and to avoid repetition, the number of studies under each study description could be presented as Ns e.g. 'Among the 34 RCT studies were those that studied the effect of: iron supplementation compared to placebo or no treatment (N = 25); iron-fortified foods compared to non-fortified foods (N = 5); etc

- Check consistency in the use of Sub-Saharan Africa or sub-Saharan Africa
- "Due to substantial heterogeneity in study methods, only seven (n=775) out of 24 studies that used the Bayley Scales of Infant Development (BSID) to assess cognitive development' - This statement is repeated under the subsection on **synthesis**.
- It is not clear what number of studies were included to investigate the effect of iron supplementation. Under the subsection on study characteristics, the number is indicated as 25. Later on, under 'cognitive development, the number is indicated as 23. Please clarify.
- Consider revising the following statement for improved readability as 'children' appears four times
'In school children, one RCT of 119 Indonesian children reported improved IQ among children with IDA at baseline who received iron supplementation for three months compared to children who received placebo.'
- There is a lot of repetition in the text under the Results section which makes reading the text quite tedious. For instance, under the subsection on 'Educational achievement,' a similar statement appears in the third and sixth lines 'four studies (n=3058) reported no beneficial effects.' Consider revising
- The authors tend to use the word 'studies' several times in single statements and should consider revisions. For example, the first statement under the subsection titled 'Effect of duration..'
- The second objective for the review was '**For comparison**, we further summarised evidence from randomised controlled trials on the effects of iron supplementation on neurobehavioral outcomes in non-African countries.' My sense is that the comparison does not really come out clearly in the results. The authors should consider providing a summary to provide this comparison, either at the end of each subsection on specific neurobehavioural outcomes or at the end of the Results section, if this fits within the journal guidelines.

Discussion

- In the first paragraph, there is discussion around the association between iron supplementation and the heightened risk of malaria infection. This information would fit better under the Introduction as it provides more context around why there are limited iron supplementation studies in Africa

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Developmental psychology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Nov 2021

Agnes Mutua, Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine Research-Coast, KEMRI Wellcome Trust Research Programme, Kilifi, Kenya

We thank the reviewer for her helpful comments, which we have addressed point-by-point below:

The authors have presented data from a systematic review and meta-analysis which found mixed evidence for the effects of iron supplementation or fortification on neurobehavioural outcomes in children. This is an area on which there is limited evidence from Africa, despite the high prevalence of both iron deficiency and developmental delay. The authors are commended for the use of a comprehensive search strategy for their review which yielded important evidence on the effects of iron supplementation on neurobehavioural outcomes in African children, while at the same time comparing their findings with those from children living in non-African countries.

I have made the following comments for consideration by the authors:

Introduction

The rationale for, and the objectives of the systematic review are clearly stated. However, I would like to suggest that the authors consider shifting some of the material in the Introduction. For instance, the second paragraph could be shifted to the beginning of this section as it gets straight to the point in providing context for the review.

Response: We agree with the reviewers point that the second paragraph provides a clearer context for our review and have now moved paragraph two under introduction to the beginning of the section as follows:

"Iron deficiency is the most common micronutrient deficiency affecting about two billion individuals globally and accounting for over 40% of all cases of anaemia ¹⁻³. Children living in Africa disproportionately bear the highest burden of anaemia and iron deficiency. Approximately 43% of pre-school children are anaemic globally and over 60% of these children live in Africa ^{1, 4}, while it is estimated that 52% of African children are iron deficient ⁵.

The first mention of 'randomised controlled trials' appears at the end of the introduction, and it is here that the abbreviation 'RCT' should appear after it has been written out in full. In later sections, the authors can just use the abbreviation, without having to spell it out in full again as they have done under the Methods and other sections.

Response: We have now abbreviated 'randomised controlled trials' in the last paragraph of the introduction and added the abbreviation RCT in the 'Search strategy and eligibility criteria', 'Study selection' and 'Conclusions' sections.

Methods

Under the subsection on the search strategy, the authors indicate that they 'searched...for studies published up to 9th March 2021.' It is not clear which month/year was considered as the start point.

Response: We thank the reviewer for this comment. For comprehensiveness, we did not restrict our search by date of publication, therefore we did not have a start date for the included studies. The earliest study we included was published in 1978. For clarification, we have now added the following statement in the 'Search strategy and eligibility criteria' section:

"The search was not restricted by language or publication date."

Additionally, we repeated our search on 22nd October 2021 and found one more RCT in Indian children. We have now updated the Abstract, Results section, Figures 1 and 2, References and Supplementary materials to reflect this addition.

'Disagreements between reviewers were resolved through discussion.' Please clarify what the disagreements were on and the content of the discussion to get to a consensus.

Response: The few disagreements were on the methods in some of the older studies. For clarification, we have now revised the sentence under the sub-section 'Study selection, data extraction and quality appraisal' as follows:

"Disagreements between reviewers on study methodologies were resolved through discussion following the pre-determined inclusion and exclusion criteria."

'We used the revised Cochrane risk-of-bias tool for randomised trials...' This statement appears twice in the same paragraph. Consider revising.

Response: Thank you. The Cochrane risk of bias tool for randomised trials is only used to assess risk of bias in individually-randomised, parallel-group trials while the Cochrane risk of bias tool for randomised trials with additional considerations for cluster-randomised trials is an extended version that is only used to assess risk of bias in cluster RCTs. We have now revised the paragraph as follows:

"We used the revised Cochrane risk-of-bias tool for randomised trials (RoB 2) to assess for risk of bias for the individually-randomised, parallel-group RCTs included in the review. RoB 2 assesses five domains of bias including bias from the randomisation process, deviations from intended interventions, missing outcome data, and bias in measurement of the outcome and selection of the reported result. To assess the risk of bias in two cluster RCTs, we used the revised Cochrane risk of bias tool for randomised trials with additional considerations for cluster-randomised trials."

'The large degree of diversity in the study variables necessitated narrative synthesis of the study findings.' Was this applied to all the studies included in the review, or only to those from Africa? Please clarify

Response: We summarized all the studies narratively and performed a secondary meta-analysis for seven studies in non-African countries that used the same tool (the Bayley Scales of Infant Development). We have now clarified that the meta-analysis was a secondary analysis and revised the sentence in the Methods section under 'Synthesis of included studies' as follows:

"The large degree of diversity in the study variables necessitated narrative synthesis of the study findings for all included studies."

We have also revised the Methods section under 'Secondary meta-analysis of seven studies in non-African countries'

"Due to the substantial variation in study methods, we did a secondary meta-analysis in a limited number of RCTs that all used the Bayley Scales of Infant Development (BSID) to assess cognitive and motor development in children living in non-African countries. None of the studies in African children used the BSID."

Results

'...that were not relevant to our study.' I suggest you use 'review' rather than 'study'

Response: We have revised 'study' to 'review'.

The information on the time period of the publications included in the review should be provided earlier, under search strategy

Response: Thank you, per comment 3 above, we have now clarified in the 'Search strategy and eligibility criteria' section that we did not restrict our search by date of publication and therefore we did not have a pre-determined start date for the included studies. Hence, we reported the time period of the included studies in the Results section.

'Of the 34 RCT studies: 25 evaluated the effect of iron supplementation compared to placebo or no treatment; five the effect of iron-fortified foods compared to non-fortified foods; one the effect of fortification of formula milk with high compared to low dosages of iron; one the effect of immediate iron supplementation given concurrently or 28 days after antimalarial treatment on development in children with severe malaria and one the effect of varying and consistent doses of iron supplementation compared to placebo; two the effects of maternal iron supplementation on neurobehavioural outcomes in children after birth.'
For clarity and to avoid repetition, the number of studies under each study description could be presented as Ns e.g. 'Among the 34 RCT studies were those that studied the effect of: iron supplementation compared to placebo or no treatment (N = 25); iron-fortified foods compared to non-fortified foods (N = 5); etc

Response: We have now edited the statement under 'Study characteristics and outcomes' in the Results as follows:

"Among the 35 RCTs were those that studied the effect of: iron supplementation compared to placebo or no treatment (n= 25), iron-fortified foods compared to non-fortified foods (n=5), formula milk fortified with high compared to low dosages of iron (n=1), immediate iron supplementation given concurrently or 28 days after antimalarial treatment on development in children with severe malaria (n=1), varying and consistent doses of iron supplementation compared to placebo (n=1), and maternal iron supplementation on neurobehavioural outcomes in children after birth (n=2)."

Check consistency in the use of Sub-Saharan Africa or sub-Saharan Africa

Response: Thank you. We have now revised 'Sub-Saharan Africa' to 'sub-Saharan Africa' in the sub-section 'Comparison of studies in African countries versus non-African countries, and in the Discussion section for consistency.

"Due to substantial heterogeneity in study methods, only seven (n=775) out of 24 studies that used the Bayley Scales of Infant Development (BSID) to assess cognitive development' - This statement is repeated under the subsection on synthesis.

Response: We have rephrased the sentence in results under the 'Cognitive development' sub-section as follows:

"Secondary meta-analysis of seven studies (n=775) provided limited evidence of beneficial effects of iron supplementation on cognitive development in pre-school children (MD=1.73, 95% CI, -1.05, 4.52) (Extended data, file 5 ²¹)."

It is not clear what number of studies were included to investigate the effect of iron supplementation. Under the subsection on study characteristics, the number is indicated as 25. Later on, under 'cognitive development, the number is indicated as 23. Please clarify.

Response: We thank the reviewer for this comment. Two of the 25 studies did not investigate the effects of iron supplementation on cognitive outcomes and were therefore not included under the

section on 'Cognitive development'.

Consider revising the following statement for improved readability as 'children' appears four times

'In school children, one RCT of 119 Indonesian children reported improved IQ among children with IDA at baseline who received iron supplementation for three months compared to children who received placebo.'

Response: We have revised the sentence in the 'Cognitive development' section in results as follows:

"One RCT (n=119) in Indonesia reported improved IQ among school children with IDA who received iron supplementation for three months compared to those who received placebo ⁵⁴."

There is a lot of repetition in the text under the Results section which makes reading the text quite tedious. For instance, under the subsection on 'Educational achievement,' a similar statement appears in the third and sixth lines 'four studies (n=3058) reported no beneficial effects.' Consider revising

Response: Thank you. We have now removed the repeated text under 'Educational achievement' and throughout the Results section more generally and have made the Results more concise to improve readability.

The authors tend to use the word 'studies' several times in single statements and should consider revisions. For example, the first statement under the subsection titled 'Effect of duration..'

Response: We agree with the reviewer that the term 'studies' has been repeated in the Results section and we have removed the repeated text from the Results section. For instance, we have revised the sub-section 'Effect of duration of supplementation or fortification' in the Results as follows:

"In total, seven studies (n=534) investigated the effect of iron supplementation for less than three months and of these studies, five (n=419) reported beneficial effects of iron supplementation on neurobehavioural outcomes, while two (n=115) reported no beneficial effects. Out of 26 studies (n=8972) that evaluated the effect of iron supplementation (n=20) or fortification (n=6) for three months or more, 13 (n=3939) reported beneficial effects of iron supplementation (n=10) or fortification (n=3) on neurobehavioural outcomes and 13 (n=5033) reported no beneficial effects of iron supplementation (n=10) or fortification (n=3)."

The second objective for the review was 'For comparison, we further summarised evidence from randomised controlled trials on the effects of iron supplementation on neurobehavioral outcomes in non-African countries.' My sense is that the comparison does not really come out clearly in the results. The authors should consider providing a summary to provide this comparison, either at the end of each subsection on specific neurobehavioural outcomes or at the end of the Results section, if this fits within the journal guidelines.

Response: Thank you. We included a paragraph titled 'Studies in African countries versus non-

African countries' in the Results after 'Study characteristics and outcomes.' We have now edited and moved this paragraph to the end of the Results and changed the title as follows for clarification:

"Comparison of studies in African countries versus non-African countries"

Five RCTs including a total of 1294 children evaluated the effect of iron supplementation or fortification on cognitive (n=4), motor (n=1), behavioural (n=1) or language (n=1) outcomes in African children. Only three out of the five studies were in sub-Saharan Africa and of the three one did not have a placebo group. Out of the five studies, two (n=647) reported beneficial effects on cognitive, motor or language outcomes only in anaemic children^{26, 27} while three (n=647) reported no beneficial effects in children^{24, 25, 28}. Of the three studies that reported no beneficial effect of iron supplementation, one included only children with ID²⁴, one had a prevalence of 21% of anaemia²⁵ while one did not report baseline iron status²⁵. Among children living in non-African countries, 30 RCTs including a total of 8694 participants investigated the effect of iron supplementation or fortification on neurobehavioural outcomes. Compared to studies in African children, over half of the 30 studies reported beneficial effects on neurobehavioural outcomes, mostly in children with ID, IDA or anaemia²⁹⁻⁵⁷."

Additionally, under each neurobehavioural outcome, we discuss African studies first, then studies from non-African countries. We have now added the following information in the methods section under the subsection 'Synthesis of included studies':

"Under each neurobehavioural domain, we first summarized studies in African countries followed by studies in non-African countries."

Discussion

In the first paragraph, there is discussion around the association between iron supplementation and the heightened risk of malaria infection. This information would fit better under the Introduction as it provides more context around why there are limited iron supplementation studies in Africa

Response: Thank you for this comment. We have now added this information to the last paragraph of the introduction section as follows:

"Despite the high prevalence of both iron deficiency and anaemia, there are few studies investigating the effects of giving iron on neurobehavioural outcomes in African children. This may be due to many factors including concern that iron supplementation may increase the risk of malaria and other infections¹⁸⁻²⁰."

Competing Interests: No competing interests were disclosed.